Carmen Ballesteros-Merino

Carmen Ballesteros-Merino

Auto-generated profile, based on publicly available information

Carmen Ballesteros-Merino

Earle A. Chiles Research Institute (a division of Providence Cancer Institute), Portland, Oregon

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
NANicola E. Annels
Nicola E. Annels
DMDavid Mansfield
David Mansfield
MAMehreen Arif
Mehreen Arif
CBCarmen Ballesteros-Merino
Carmen Ballesteros-Merino
GSGuy R. Simpson
Guy R. Simpson
HPHardev Pandha
Hardev Pandha
Purpose: The CANON [CAVATAK in NON–muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer.Patients and Methods: Fifteen patients enrolled in this “window of opportunity” phase I study, exposing primary bladder cancers to CAVATAK prior to surgery. The first 9 patients received intravesical administration of monotherapy CAVATAK; in the second stage, 6 patients received CAVATAK with a subtherapeutic dose of mitomycin C, known to enhance expression of ICAM-1 on bladder cancer cells. The primary endpoint was to determine patient safety and maximum tolerated dose (MTD). Secondary endpoints were evidence of viral replication, induction of inflammatory cytokines, antitumor activity, and viral-induced changes in resected tissue.Results: Clinical activity of CAVATAK was demonstrated by induction of tumor inflammation and hemorrhage following either single or multiple administrations of CAVATAK in multiple patients, and a complete resolution of tumor in 1 patient. Whether used alone or in combination with mitomycin C, CAVATAK caused marked inflammatory changes within NMIBC tissue biopsies by upregulating IFN-inducible genes, including both immune checkpoint inhibitory genes (PD-L1 and LAG3) and Th1-associated chemokines, as well as the induction of the innate activator RIG-I, compared with bladder cancer tissue from untreated patients. No significant toxicities were reported in any patient, from either virus or combination therapy.Conclusions: The acceptable safety profile of CAVATAK, proof of viral targeting, replication, and tumor cell death together with the virus-mediated increases in “immunological heat” within the tumor microenvironment all indicate that CAVATAK may be potentially considered as a novel therapeutic for NMIBC.

16 February 2021 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
MTMelinda L. Telli
Melinda L. Telli
HNHiroshi Nagata
Hiroshi Nagata
IWIrene Wapnir
Irene Wapnir
CAChaitanya R. Acharya
Chaitanya R. Acharya
KZKaitlin Zablotsky
Kaitlin Zablotsky
Erika CrosbyErika Crosby
Erika Crosby
Purpose: Triple-negative breast cancer (TNBC) is an aggressive disease with limited therapeutic options. Antibodies targeting programmed cell death protein 1 (PD-1)/PD-1 ligand 1 (PD-L1) have entered the therapeutic landscape in TNBC, but only a minority of patients benefit. A way to reliably enhance immunogenicity, T-cell infiltration, and predict responsiveness is critically needed.Patients and Methods: Using mouse models of TNBC, we evaluate immune activation and tumor targeting of intratumoral IL12 plasmid followed by electroporation (tavokinogene telseplasmid; Tavo). We further present a single-arm, prospective clinical trial of Tavo monotherapy in patients with treatment refractory, advanced TNBC (OMS-I140). Finally, we expand these findings using publicly available breast cancer and melanoma datasets.Results: Single-cell RNA sequencing of murine tumors identified a CXCR3 gene signature (CXCR3-GS) following Tavo treatment associated with enhanced antigen presentation, T-cell infiltration and expansion, and PD-1/PD-L1 expression. Assessment of pretreatment and posttreatment tissue from patients confirms enrichment of this CXCR3-GS in tumors from patients that exhibited an enhancement of CD8+ T-cell infiltration following treatment. One patient, previously unresponsive to anti–PD-L1 therapy, but who exhibited an increased CXCR3-GS after Tavo treatment, went on to receive additional anti–PD-1 therapy as their immediate next treatment after OMS-I140, and demonstrated a significant clinical response.Conclusions: These data show a safe, effective intratumoral therapy that can enhance antigen presentation and recruit CD8 T cells, which are required for the antitumor efficacy. We identify a Tavo treatment-related gene signature associated with improved outcomes and conversion of nonresponsive tumors, potentially even beyond TNBC.

26 December 2023 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
DKDavid A. Knorr
David A. Knorr
LBLucas Blanchard
Lucas Blanchard
RLRom Leidner
Rom Leidner
SJShawn M. Jensen
Shawn M. Jensen
RMRyan Meng
Ryan Meng
JRJeffrey V. Ravetch
Jeffrey V. Ravetch
Preclinical murine data indicate that fragment crystallizable (Fc)-dependent depletion of intratumoral regulatory T cells (Treg) is a major mechanism of action of anti–CTLA-4. However, the two main antibodies administered to patients (ipilimumab and tremelimumab) do not recapitulate these effects. Here, we investigate the underlying mechanisms responsible for the limited Treg depletion observed with these therapies. Using an immunocompetent murine model humanized for CTLA-4 and Fcγ receptors (FcγR), we show that ipilimumab and tremelimumab exhibit limited Treg depletion in tumors. Immune profiling of the tumor microenvironment (TME) in both humanized mice and humans revealed high expression of the inhibitory Fc receptor, FcγRIIB, which limits antibody-dependent cellular cytotoxicity/phagocytosis. Blocking FcγRIIB in humanized mice rescued the Treg-depleting capacity and antitumor activity of ipilimumab. Furthermore, Fc engineering of antibodies targeting Treg-associated targets (CTLA-4 or CCR8) to minimize FcγRIIB binding significantly enhanced Treg depletion, resulting in increased antitumor activity across various tumor models. Our results define the inhibitory FcγRIIB as an immune checkpoint limiting antibody-mediated Treg depletion in the TME, and demonstrate Fc engineering as an effective strategy to overcome this limitation and improve the efficacy of Treg-targeting antibodies.

5 April 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
VRVenkatesh Rajamanickam
Venkatesh Rajamanickam
CBCarmen Ballesteros-Merino
Carmen Ballesteros-Merino
KSKimberly Samson
Kimberly Samson
DRDavid Ross
David Ross
BBBrady Bernard
Brady Bernard
TDThomas Duhen
Thomas Duhen
Microsatellite-stable (MSS) colorectal cancers are characterized by low mutation burden and limited immune-cell infiltration and thereby respond poorly to immunotherapy. Here, we report a case of metastatic MSS colorectal cancer with a robust anticancer immune response. The primary tumor was resected in 2012, and the patient received several cycles of chemotherapy until 2017. In 2018, the patient underwent a left hepatectomy to remove a new metastasis. Analysis of the metastatic tumor revealed a strong CD8+ T-cell response. A high frequency of CD8+ T cells coexpressed CD39 and CD103, a phenotype characteristic of tumor-reactive cells. Using whole-exome sequencing, we identified somatic mutations that generated peptides recognized by CD39+CD103+CD8+ T cells. The observed reactivity against the tumor was dominated by the response to a single mutation that emerged in the metastasis. Somatic mutations that were not immunogenic in the primary tumor led to robust CD8+ T-cell expansion later during disease progression. Our data suggest that the cytotoxic treatment regimen received by the patient might be responsible for this effect. Hence, the capacity of cytotoxic regimens to prime the immune system in colorectal cancer patients should be investigated further and might provide a rationale for combination with immunotherapy.

1 December 2018 in Revista Lasallista de Investigación
Verified
Journal Article
Open access
PDF file
CBCarmen Ballesteros
Carmen Ballesteros
GGGabriela Gracia
Gabriela Gracia
AOAndrea Ocaña
Andrea Ocaña
CJCory Jácome
Cory Jácome
La identidad cultural representa los valores, orgullos, costumbres, creencias y comportamientos que forman parte de un grupo social y que actúan con la misión de engendrar un sentimiento de pertenencia. Esta cultura se puede convertir en el pilar primordial de cada localidad; por lo cual es necesario resguardar la, defenderla y ampararse, para que dicha fortaleza pueda convertirse en una ventaja competitiva. Objetivo. Analizar la promoción cultural como herramienta para fortalecer la identidad afro esmeraldeña. Materiales y métodos. Constan entrevistas efectuadas a personas expertas en el área de arte, cultura y promoción, así como a personajes destacados en las distintas disciplinas que enmarcan la cultura de Esmeraldas como lo son la poesía, el canto, la pintura, la escultura, la música, la marimba y el deporte. Además del aporte de la ciudadanía a través de encuestas y entrevistas. Resultados. Los personajes destacados dentro de la cultura esmeraldeña indican que se sienten satisfechos por la labor que han realizado. Se identificó que los ciudadanos se sienten muy identificados (35%) o identificados (47%) con la cultura afroesmeraldeña; y el mayor rasgo identitario es la marimba, con un 45%. Sin embargo el 23% no asiste a ningún evento cultural en la ciudad por falta de difusión. Conclusiones. La investigación permitió determinar que fortalecer la identidad afro esmeraldeña es una tarea compleja que debe de fomentarse en el hogar y las instituciones educativas. Finalmente las investigadoras recomiendan ejecutar estrategias de creación y difusión de productos culturales para conservar y proteger la identidad cultural afro esmeraldeña.

31 March 2023
Verified
Other
Open access
NANicola E. Annels
Nicola E. Annels
DMDavid Mansfield
David Mansfield
MAMehreen Arif
Mehreen Arif
CBCarmen Ballesteros-Merino
Carmen Ballesteros-Merino
GSGuy R. Simpson
Guy R. Simpson
HPHardev S. Pandha
Hardev S. Pandha